184 results on '"Corn, Paul G."'
Search Results
2. Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND
3. Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
4. Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone-tumor microenvironment through Wnt pathway-induced M2 macrophage polarization.
5. Radium-223 Treatment Produces Prolonged Suppression of Resident Osteoblasts and Decreased Bone Mineral Density in Trabecular Bone in Osteoblast Reporter Mice.
6. Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer
7. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer
8. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial
9. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial
10. Taxane-based Combination Therapies for Metastatic Prostate Cancer
11. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era
12. Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin
13. Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing
14. Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma
15. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy
16. Sunitinib Plus Androgen Deprivation and Radiation Therapy for Patients With Localized High-Risk Prostate Cancer: Results From a Multi-institutional Phase 1 Study
17. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era
18. Src signaling pathways in prostate cancer
19. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases
20. Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates
21. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer
22. Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer
23. Multimodal kidney‐preserving approach in localised and locally advanced high‐risk upper tract urothelial carcinoma.
24. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome
25. Response: Re: Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
26. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer
27. Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
28. Metastases-Targeting Radiotherapy and ADT—Reply.
29. Frequent hypermethylation of the 5′ CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer
30. Enzalutamide-induced 'BRCAness' and PARP inhibition is a synthetic lethal therapy for castration-resistant prostate cancer
31. Targeting DNA damage response in prostate cancer through inhibition of androgen receptor/CDC6-ATR-Chk1 signaling: Combined AR/CDC6 and Chk1/2 inhibition for PCa
32. Fibroblast growth factors signaling in bone metastasis.
33. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer.
34. Amplification Status of Capsule Genes in Haemophilus influenzae Type b Clinical Isolates
35. Genes Involved in Haemophilus influenzae Type b Capsule Expression Are Frequently Amplified
36. Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase I study
37. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
38. Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit
39. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
40. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
41. The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study.
42. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
43. Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study.
44. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.
45. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial.
46. The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development.
47. MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines.
48. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.
49. Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer.
50. Hypoxic regulation of mRNA expression.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.